Novartis | NOVN - Equity Capital And Reserves


Novartis reported $41.95B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Alcon AG USD 21.6B 538M Jun/2026
Almirall EUR 1.53B 43.26M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Autolus Therapeutics Ltd USD 74.84M 33.99M Jun/2026
Bayer EUR 29.71B 863M Jun/2026
Biogen USD 18.85B 196.3M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Fresenius EUR 19.7B 766M Jun/2026
Fresenius Medical Care EUR 13.53B 673.44M Jun/2026
Genmab DKK 5.96B 275M Jun/2026
Gilead Sciences USD 11.74B 11.77B Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
J&J USD 84.97B 3.78B Jun/2026
Lakefront Biotherapeutics EUR 3.26B 10.26M Jun/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 30.17B 430M Jun/2026
Merck USD 41.93B 3.94B Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Novo Nordisk DKK 221.28B 18.21B Jun/2026
Orion EUR 1.27B 146.5M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Philips EUR 11.48B 84M Jun/2026
Recordati EUR 2.13B 70.34M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025